We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Cambridge Cognition Holdings Plc | LSE:COG | London | Ordinary Share | GB00B8DV9647 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 52.00 | 51.00 | 53.00 | 52.00 | 52.00 | 52.00 | 3,759 | 08:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 12.61M | -409k | -0.0117 | -44.44 | 18.12M |
From Apr 2019 to Apr 2024
TIDMCOG
RNS Number : 1347L
Cambridge Cognition Holdings PLC
29 September 2016
29 September 2016
Cambridge Cognition Holdings Plc
('Cambridge Cognition' or the 'Company')
Major contract wins for CANTAB Connect
The neuroscience company Cambridge Cognition Holdings PLC (Cambridge, UK - LSE: COG), which develops and markets near patient technologies to facilitate early intervention and development of treatments for neurological disorders, today announces the signing of two major contracts using the Company's CANTAB Connect technology.
The contracts totalling US$3.67million (GBP2.82 million) are with US biopharmaceutical companies for late stage clinical trials and will contribute US$1.07 million (GBP0.82 million) to reported revenue in the second half of 2016.
The award of the contracts was expected and so the outlook for the current year remains unchanged.
Steven Powell, PhD, Chief Executive Officer, Cambridge Cognition: "Securing these contracts is further evidence of the concerted effort being made to accelerate revenue growth from our core businesses in Academic Research and Pharmaceutical Clinical Trials. Not only do we expect to secure further business from core CANTAB Connect products such as those used in the above contracts, but also products such as CANTAB Recruit and Cognition Kit which we introduced into our product portfolio earlier this year."
Notes to editors
About Cambridge Cognition
Cambridge Cognition is an international neuroscience company which develops and markets near patient cognitive assessment products to improve the understanding, diagnosis and treatment of neurological and psychiatric disorders.
For over 30 years the company's patented technology has advanced the assessment of cognition to accelerate the development of safe and effective treatments, improve patient outcomes and measure cognitive health throughout life.
Partners include the world's leading biotechnology and pharmaceutical companies, academic institutions and public-private healthcare providers.
www.cambridgecognition.com
Enquiries
Hot Features
Premium
Cambridge Cognition Holdings PLC
Steven Powell, Chief Executive Tel: 01223 810
Officer 700
Noah Konig, Director of Product press@camcog.com
Marketing and Communications
finnCap Ltd (NOMAD and Joint Broker) Tel: 020 7220
0500
Geoff Nash / Simon Hicks (Corporate Finance)
Alice Lane (Corporate Broking)
Hybridan LLP (Joint Broker) Tel: 020 3764
2341
Claire Noyce (Corporate Broking)
This information is provided by RNS
The company news service from the London Stock Exchange
END
CNTUWANRNVAKUAR
(END) Dow Jones Newswires
September 29, 2016 02:00 ET (06:00 GMT)
1 Year Cambridge Cognition Chart |
1 Month Cambridge Cognition Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
